Charcot-marie-tooth disease subtypes and genetic testing strategies

Annals of Neurology

Volumn 69, Issue 1, 2011, Pages 22-33

  Saporta, Anita S D ^a   Sottile, Stephanie L ^a   Miller, Lindsey J ^a   Feely, Shawna M E ^a   Siskind, Carly E ^a   Shy, Michael E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE CLASSIFICATION; DOMINANT INHERITANCE; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; NEUROPATHY; ONSET AGE; PHENOTYPIC VARIATION; PRIORITY JOURNAL;

ACTION POTENTIALS; ADULT; AGE OF ONSET; CHARCOT-MARIE-TOOTH DISEASE; CHILD DEVELOPMENT; FEMALE; GENETIC TESTING; HUMANS; INFANT; MALE; MUTATION; NEURAL CONDUCTION; PEDIGREE; PHENOTYPE; ULNAR NERVE; WALKING;

EID: 79551488413     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22166     Document Type: Article

References (25)

1. Charcot J, Marie P,. [On a particular form of progressive muscular atrophy, often familial, commencing with the feet and the legs and later reaching the hands.] Sur une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jamber et atteingnant plus tard les mains. Revue de Médecine 1886; 6: 97-138. [French]
2. Tooth H,. The peroneal type of progressive muscular atrophy. London: Lewis, 1886.
3. Skre H,. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974; 6: 98-118.
4. Harding AE, Thomas PK,. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980; 103: 259-280.
5. Harding AE, Thomas PK,. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980; 17: 329-336.
6. Shy M, Lupski JR, Chance PF, et al. The hereditary motor and sensory neuropathies: an overview of the clinical, genetic, electrophysiologic and pathologic features. In:, Dyck PJ, Thomas PK, eds. Peripheral neuropathy. Vol. 2. 4th ed. Philadelphia: WB Saunders, 2005: 1623-1658.
7. England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72: 177-184.
8. England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72: 185-192.
9. Verhoeven K, Claeys KG, Zuchner S, et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 2006; 129: 2093-2102.
10. Lawson VH, Graham BV, Flanigan KM,. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 2005; 65: 197-204.
11. Kijima K, Numakura C, Izumino H, et al. Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum Genet 2005; 116: 23-27.
12. Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-451.
13. Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123: 1516-1527.
14. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008; 70: 378-383.
15. Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68: 849-855.
16. Shy ME, Jani A, Krajewski KM, et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127: 371-384.
17. Lewis RA, Sumner AJ, Shy ME,. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 2000; 23: 1472-1487.
18. England JD, Gronseth GS, Franklin G, et al. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 2009; 39: 116-125.
19. England JD, Gronseth GS, Franklin G, et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). PM R 2009; 1: 5-13.
20. Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996; 4: 25-33.
21. Dubourg O, Azzedine H, Verny C, et al. Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8: 75-86.
22. Li J, Krajewski K, Lewis RA, Shy ME,. Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. Muscle Nerve 2004; 29: 205-210.
23. Li J, Krajewski K, Shy ME, Lewis RA,. Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology 2002; 58: 1769-1773.
24. Krajewski KM, Shy ME,. Genetic testing in neuromuscular disease. Neurol Clin 2004; 22: 481-508, v.
25. American Society of Human Genetics Board of Directors, Directors ACoMGBo,. ASHG/ACMG REPORT Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am J Hum Genet 1995; 57: 1233-1241.